Emrusolmin

Emrusolmin
Clinical data
Other names	Anle138b, TEV-56286
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 5-(1,3-benzodioxol-5-yl)-3-(3-bromophenyl)-1H-pyrazole;
CAS Number	882697-00-9;
PubChem CID	44608289;
DrugBank	DB13927;
ChemSpider	58825097;
UNII	E7WRA77JET;
KEGG	D80685;
ChEBI	CHEBI:232606;
ChEMBL	ChEMBL4748063;
Chemical and physical data
Formula	C16H11BrN2O2
Molar mass	343.180 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1OC2=C(O1)C=C(C=C2)C3=CC(=NN3)C4=CC(=CC=C4)Br;
	InChI InChI=InChI=1S/C16H11BrN2O2/c17-12-3-1-2-10(6-12)13-8-14(19-18-13)11-4-5-15-16(7-11)21-9-20-15/h1-8H,9H2,(H,18,19); Key:RCQIIBJSUWYYFU-UHFFFAOYSA-N;

Emrusolmin (development code Anle138b) is an experimental drug for the treatment of neurodegenerative diseases. It is an inhibitor of protein aggregation, particularly preventing the aggregation of α-synuclein which is implicated in the development of Parkinson's disease.^[1]^[2]^[3] Other proteins it inhibits the aggregation of include tau^[4] which is associated with Alzheimer's disease (AD) and tauopathy, and amyloid beta^[5] which is associated with AD.